Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis

Table 1 Incidence and duration of paralytic relapses in EAE mice after cell treatment

Treatment group	Incidence of relapse^{a, b}	Relapse rate (%)	Duration of relapse^c
Treatment group	Incidence of relapse^{a, b}	Relapse rate (%)	Median	Mean ± SD	CI (95 %)
Control (PBS)	31 (44)	70.5	20.0	17.0 ± 9.6	13.6–20.4
MIC_Cop	5 (30)	16.7	4.0	6.6 ± 5,0	2.2–11.0
MIC	4 (7)	57.1	6.5	9.50 ± 8.4	1.3–17.7
SPC_Cop	8 (15)	53.3	13.5	14.5 ± 6,6	9.9–19.1
UVC-SPC_Cop	15 (15)	100	24.0	19.6 ± 7.7	15.7–23.5

Treatment groups were compared using Fisher’s exact test (incidence of relapse) and One-tail Mann–Whitney U test (duration of relapse): * p < 0.05, ** p < 0.01, *** p < 0.001
CI confidence interval; EAE experimental autoimmune encephalomyelitis; MIC mitomycin C-induced cells; MIC _Cop Copaxone^®-loaded mitomycin C-induced cells; PBS phosphate-buffered saline; SD standard deviation; SPC _Cop Copaxone^®-loaded splenocytes; UVC-SPC _Cop Copaxone^®-loaded ultraviolett C-irradiated splenocytes
^aIncidence of relapse: number of mice with relapse (total number of animals) in treatment group
^b Incidence of relapse MIC_Cop vs. control, *** p < 0.0001; MIC vs. control, p = 0.66; SPC_Cop vs. control, * p = 0.026; UVC-SPC_Cop vs. control, * p = 0.034; MIC_Cop vs. MIC,* p = 0.045; MIC_Cop vs. SPC_Cop, *** p < 0.0001; MIC_Cop vs. UVC-SPC_Cop, * p = 0.016; MIC vs. SPC_Cop, p = 1.00; MIC vs. UVC-SPC_Cop, * p = 0.022; SPC_Cop vs. UVC-SPC_Cop, ** p = 0.006
^c Duration of relapse MIC_Cop vs. control, * p = 0.017; MIC vs. control, p = 0.063; SPC_Cop vs. control, p = 0.266; UVC-SPC_Cop vs. control, p = 0.755; MIC_Cop vs. MIC, p = 0.476; MIC_Cop vs. SPC_Cop, * p = 0.024; MIC_Cop vs. UVC-SPC_Cop, ** p = 0.005; MIC vs. SPC_Cop, p = 0.107; MIC vs. UVC-SPC_Cop, * p = 0.026; UVC-SPC_Cop vs. SPC_Cop, p = 0.945

ISSN: 1479-5876